<DOC>
	<DOCNO>NCT01331707</DOCNO>
	<brief_summary>The introduction drug-eluting stent ( DES ) treatment coronary artery disease lead significant reduction morbidity demand DES performance . Such demand optimize performance challenge coronary lesion ; third generation DES develop effort improve DES performance challenge lesion . Two CE-certified third generation DES ( Resolute Integrity Promus Element stent ) currently available ; data indicate advantage one DES .</brief_summary>
	<brief_title>DUrable Polymer-based STent CHallenge Promus Element Versus ReSolute Integrity All Comers Population</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Minimum age 18 year ; Coronary artery disease lesion ( ) eligible treatment drug elute stent accord clinical guideline and/or operator ' judgement ; Patient willing able cooperate study procedure require followup visit ; patient inform agrees participation sign EC approve write informed consent . Participation another randomize drug device study reach primary endpoint ; Planned surgery within 6 month PCI unless dual antiplatelet therapy maintain throughout perisurgical period ; Intolerance P2Y12 receptor antagonist result patient 's inability adhere dualantiplatelet therapy , intolerance aspirin , heparin , component two DES examine ; Known pregnancy ; Life expectancy less 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>drug-eluting stent</keyword>
	<keyword>Zotarolimus</keyword>
	<keyword>Everolimus</keyword>
	<keyword>comer population</keyword>
	<keyword>target vessel failure</keyword>
	<keyword>coronary artery disease</keyword>
</DOC>